{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibve6c6jywk63ymy7jnmrcgdaneipo7jgh75hdp43gg7r6uqnb7su",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3miyenepirgy2"
  },
  "path": "/2026/04/08/supira-medical-announces-fda-approval-for-support-ii-pivotal-trial-advances-in-cardiogenic-shock-and-appointment-of-d-keith-grossman-to-board-of-directors/",
  "publishedAt": "2026-04-08T12:03:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "Milestones underscore clinical progress and strengthen commercial foundation LOS GATOS, Calif., April 8, 2026 /PRNewswire/ — Supira Medical, Inc. (Supira), a clinical-stage company focused on transforming the percutaneous ventricular assist device (pVAD) market, today announced FDA approval to initiate the SUPPORT II Pivotal Trial. The trial is designed to support a future PMA submission and represents a […]",
  "title": "Supira Medical Announces FDA Approval for SUPPORT II Pivotal Trial, Advances in Cardiogenic Shock, and Appointment of D. Keith Grossman to Board of Directors"
}